{"title":"Research progress on the clinical application of lopinavir/ritonavir for the treatment of coronavirus infection","authors":"Ye Pu","doi":"10.16505/j.2095-0136.2021.0001","DOIUrl":"https://doi.org/10.16505/j.2095-0136.2021.0001","url":null,"abstract":"In the face of the sudden outbreak of novel coronavirus pneumonia (coronavirusdisease-19, COVID-19), the research and development of new antiviral drugs requires a certain amount of time and cost, and it is urgent to find safe and effective antiviral drugs that can be used clinically. Lopinavir/ritonavir (lopinavir/ritonavir, LPV/r) is a commonly used antiviral drug against adult or child human immunodeficiency virus (humanimmunodeficiency, HIV) infections. Past animal trials and clinical experience suggest It is expected to have a certain anti-viral efficacy against the new coronavirus in the fight against severe acute respiratory syndrome (Severe acute respiratory syndrome, SARS) and Middle East respiratory syndrome (Midle East respiratory syndrome, MERS). drug. Especially for patients with mild infections, the combination of drugs seems to be expected to exert a better effect, but it is necessary to pay attention to the issue of drug safety and use drugs with caution. This article aims to review the clinical research progress of LPV/r anti-coronavirus infection treatment for clinical reference.","PeriodicalId":380988,"journal":{"name":"Chinese Journal of Viral Diseases","volume":"104 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127150557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical analysis of 71 COVID-19 death cases in Wuhan","authors":"Chaoe Zhou","doi":"10.16505/j.2095-0136.2021.0005","DOIUrl":"https://doi.org/10.16505/j.2095-0136.2021.0005","url":null,"abstract":"Objective To study the factors influencing the death of the novel coronavirus disease 2019 (COVID-19) patients in Wuhan city of China. Methods The clinical data of 71 COVID-19 death cases admitted and treated in the Third Hospital of Wuhan were retrospectively analyzed. and SPSS 22.0 software was used for statistical analysis to compare the laboratory results in different periods of the disease. Results Males (64.79%. 46/71) accounted for a large proportion of the 71 cases of COVID-19 deaths in Wuhan city of China. The median age was 70.0 years old. 81.69% (58/71) were over 60 years old. People with underlying diseases accounted for 76.06% (54/71). the most common underlying disease was hypertension (53.52%. 38/71). and the most common clinical symptom was fever (85.91%. 61/71). The majority of the patients were severe type (56.34%. 40/71) at the time when they were admitted to the hospital. According to the laboratory results. their lactate dehydrogenase (LDH) [469.50 (454.50~552.75) U/L], blood glucose [9.95 (6.83~13.95) mmol/L] at the end stage were higher than that at admission with LDH [144.00 (123.75~273.25) U/L] and blood glucose [6.60 (5.20~10.70) mmol/L] (Z= -3.298, -2.542, both P < 0.05). Blood gas analysis at the end stage showed that their pH value [7.31 (7.27~7.34)]. oxygen partial pressure (PaO2) [45.00 (35.00~56.00) mm Hg] were lower than that at admission with the pH value [7.38 (7.34~7.41)] and PaO2 [82.50 (77.50~88.50) mm Meanwhile. their partial pressure of carbon dioxide (PaCO2) [59.00 (48.75~60.75) mm Hg] was higher than that at admission [42.00 (37.25~48.75) mm Hg] (Z= -2.906. -3.296. -3.206. all P < 0.05). Conclusions Elder age and combined underlying diseases account for a higher proportion of deaths. Lung injury. hypoxemia. myocardial injury, and abnormal glucose metabolism caused by the disease are the major causes of death in COVID-19 patients in Wuhan city of China.","PeriodicalId":380988,"journal":{"name":"Chinese Journal of Viral Diseases","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128115047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}